

Targeting Trends

Reporting the latest news in Molecular Surgery

The Biologically Active Cholecystokinin (26-33) peptide, [Tyr²-SO₃]CCK-8, Retains High Affinity for CCK₂ Receptors after Covalent Conjugation to Saporin

Josephine Lai, Wenjun Zhang, Hamid Badghisi, Victor J. Hruby¹ and Frank Porreca,
Departments of Pharmacology and Chemistry¹, The University of Arizona, Tucson, AZ 85724.

Cholecystokinin (CCK) is widely distributed in the central nervous system and the gastrointestinal tract. The 33-amino acid peptide contains a carboxyl terminal octapeptide sequence Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH₂ which confers the biological activity of CCK, and where the tyrosine residue occurs in sulfated form. This octapeptide, CCK-8(SO₃), has high affinity for the two structurally-defined CCK receptor types, CCK₁ and CCK₂. A covalent conjugate of CCK-8(SO₃) to saporin (CCK-8(SO₃)-SAP) was synthesized and evaluated for the toxin conjugate's affinity for the human CCK₂ receptors in transfected HEK293 cells (Figure 1). The K_i value of CCK-8(SO₃) for the CCK₂ receptors was 3.6 nM (log K_i = -8.4 ± 0.09, n = 6), and that of CCK-8(SO₃)-SAP was 3.2 nM (log K_i = -8.5 ± 0.02, n = 2). Thus, the conjugation of saporin to CCK-8(SO₃) does not significantly alter the affinity of CCK-8(SO₃) for CCK₂ receptors and should be effective in the targeted-lesion of CCK₂-expressing cells by CCK mediated internalization of saporin.

Furthermore, based on the saturation analysis of [¹²⁵I]CCK-8(SO₃) for the hCCK₁ and hCCK₂ receptors, the peptide has similar affinity for the two receptor types (K_d values are 1.9 ± 0.2 nM and 1.3 ± 0.4 nM for hCCK₁ and hCCK₂ receptors, respectively). It is reasonable to predict that CCK-8(SO₃)-SAP has similar affinity for both CCK receptor types, while the non-sulfated CCK-8-SAP is likely to be selective for the CCK₂ receptors, albeit with lower affinity (56 nM; see *Targeting Trends* 4(3):5). It should be noted also that the sulfated

group on CCK-8(SO₃) may be hydrolyzed upon storage; thus the affinity of the toxin conjugate should be verified experimentally prior to application.

We evaluated the effect of CCK-8(SO₃)-SAP on CCK₂ receptor-expressing cells in the rostral ventromedial medulla (RVM) of rats by the stereotaxic microinjection of a single dose of CCK-8(SO₃)-SAP (3 pmoles, bilaterally at 1.5 pmoles in 0.5 μL per side) into the RVM of anesthetized rats. Separate groups of rats were given the same dose of either saporin or CCK-8(SO₃) as control. All animal use and procedures were reviewed and approved by IACUC. Twenty-eight days after the RVM

(continued on page 6)

Inside this issue:

Targeting Topics	
<i>Scientific References</i>	3
Targeting Talk	
<i>LPS Content</i>	5
Targeting Tools	
<i>Featured Products</i>	7
Targeting Teaser	
<i>Word Quiz</i>	8

Newsletter Highlights

- ◆ Surf Contest (page 2)
- ◆ Teaser Winners (page 2)
- ◆ 2005 SfN Poster Award Winner (page 6)
- ◆ Streptavidin-ZAP (page 7)

Denise Higgins, Editor



Figure 1. [¹²⁵I]-CCK-8(SO₃) / Ligand competition in transfected HEK 293 cells that express hCCK₂ receptors.

Data represent mean % standard error from at least 2 independent experiments. Non-specific binding was defined by the amount of [¹²⁵I]-CCK-8(SO₃) bound in the presence of 1 μM CCK-8(SO₃).

